File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)

TitleTreatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)
Authors
Keywordschildren
China
collaborative group
medulloblastoma
multidisciplinary
Issue Date2021
PublisherOxford University Press: Open Access Journals. The Journal's web site is located at https://academic.oup.com/noa
Citation
Neuro-Oncology Advances, 2021, v. 3 n. 1, p. article no. vdab134 How to Cite?
AbstractBackground: Medulloblastoma (MB) is the most common malignant central nervous system tumor of childhood. Management requires interdisciplinary care and is associated with unique challenges in developing regions. Here, we report the characteristics, clinical outcome and treatment barriers for Chinese children with MB based on a multi-institutional cohort from the Chinese Children’s Cancer Group (CCCG). Methods: Retrospective cohort study among 12 Chinese pediatric oncology units from the CCCG Brain Tumor Workgroup on patients aged <18 years diagnosed with MB from 2016 to 2019. Results: 221 patients (male:female = 138:83) were included, 175 (79%) were ≥3 years of age, and 46 (21%) <3 years. 177 patients (80%) were completely staged, among which 50 (28%) had metastasis and 70 (40%) were considered to have high-risk (HR) disease. Gross/near-total resection was achieved in 203 patients (92%). In patients where molecular grouping could be assigned, 19 (16%), 35 (29%), and 65 (54%), respectively had WNT-activated, SHH-activated, and Group 3/4 MB. The median duration between resection and initiation of adjuvant therapy was 36 days. Respective 2-year PFS and OS rates were 76.0 ± 3.0% and 88.0 ± 2.3%. PFS was significantly associated with age, metastatic status and clinical risk grouping. Chemotherapy use during CSI or alkylator choice were not significant predictors for patient outcome. Conclusions: We reported the clinical profiles and outcome from the largest cohort of Chinese children with MB after multi-modal therapy. Strengths and limitations on the local provision of neuro-oncology service are identified.
Persistent Identifierhttp://hdl.handle.net/10722/308510
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 0.715
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, APY-
dc.contributor.authorZhen, Z-
dc.contributor.authorYang, Q-
dc.contributor.authorYuan, X-
dc.contributor.authorMa, X-
dc.contributor.authorChen, J-
dc.contributor.authorWang, J-
dc.contributor.authorYang, L-
dc.contributor.authorGuo, H-
dc.contributor.authorJiang, L-
dc.contributor.authorWeng, W-
dc.contributor.authorHuang, L-
dc.contributor.authorLiu, W-
dc.contributor.authorWang, J-
dc.contributor.authorWu, S-
dc.contributor.authorZeng, J-
dc.contributor.authorJiang, M-
dc.contributor.authorHe, K-
dc.contributor.authorGe, M-
dc.contributor.authorCheng, KKF-
dc.contributor.authorHo, WWS-
dc.contributor.authorLi, C-
dc.contributor.authorYu, L-
dc.contributor.authorZhu, S-
dc.contributor.authorNg, HK-
dc.contributor.authorChan, GCF-
dc.contributor.authorSun, X-
dc.date.accessioned2021-12-01T07:54:18Z-
dc.date.available2021-12-01T07:54:18Z-
dc.date.issued2021-
dc.identifier.citationNeuro-Oncology Advances, 2021, v. 3 n. 1, p. article no. vdab134-
dc.identifier.issn2046-2069-
dc.identifier.urihttp://hdl.handle.net/10722/308510-
dc.description.abstractBackground: Medulloblastoma (MB) is the most common malignant central nervous system tumor of childhood. Management requires interdisciplinary care and is associated with unique challenges in developing regions. Here, we report the characteristics, clinical outcome and treatment barriers for Chinese children with MB based on a multi-institutional cohort from the Chinese Children’s Cancer Group (CCCG). Methods: Retrospective cohort study among 12 Chinese pediatric oncology units from the CCCG Brain Tumor Workgroup on patients aged <18 years diagnosed with MB from 2016 to 2019. Results: 221 patients (male:female = 138:83) were included, 175 (79%) were ≥3 years of age, and 46 (21%) <3 years. 177 patients (80%) were completely staged, among which 50 (28%) had metastasis and 70 (40%) were considered to have high-risk (HR) disease. Gross/near-total resection was achieved in 203 patients (92%). In patients where molecular grouping could be assigned, 19 (16%), 35 (29%), and 65 (54%), respectively had WNT-activated, SHH-activated, and Group 3/4 MB. The median duration between resection and initiation of adjuvant therapy was 36 days. Respective 2-year PFS and OS rates were 76.0 ± 3.0% and 88.0 ± 2.3%. PFS was significantly associated with age, metastatic status and clinical risk grouping. Chemotherapy use during CSI or alkylator choice were not significant predictors for patient outcome. Conclusions: We reported the clinical profiles and outcome from the largest cohort of Chinese children with MB after multi-modal therapy. Strengths and limitations on the local provision of neuro-oncology service are identified.-
dc.languageeng-
dc.publisherOxford University Press: Open Access Journals. The Journal's web site is located at https://academic.oup.com/noa-
dc.relation.ispartofNeuro-Oncology Advances-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectchildren-
dc.subjectChina-
dc.subjectcollaborative group-
dc.subjectmedulloblastoma-
dc.subjectmultidisciplinary-
dc.titleTreatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children’s Cancer Group (CCCG)-
dc.typeArticle-
dc.identifier.emailLiu, APY: apyliu@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityLiu, APY=rp01357-
dc.identifier.authorityChan, GCF=rp00431-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1093/noajnl/vdab134-
dc.identifier.pmid34693286-
dc.identifier.pmcidPMC8528264-
dc.identifier.hkuros330646-
dc.identifier.volume3-
dc.identifier.issue1-
dc.identifier.spagearticle no. vdab134-
dc.identifier.epagearticle no. vdab134-
dc.identifier.isiWOS:000905125400139-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats